News

An expedition is planning to take clients up the world's tallest mountain in record time with xenon gas. But some in the ...
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK ... has officially approved the New Drug Application (NDA) for VELSIPITY ® (etrasimod) for the treatment of adult ...
The 2025 climbing season in the Himalayas has begun without controversy. Climbing techniques have evolved over centuries, often creating controversy and debate.
NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s ...
Everest Medicines (HKEX 1952,“Everest”, or the Company), a biopharmaceutical company focused on the discovery, c ...
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK ... has officially approved the New Drug Application (NDA) for VELSIPITY ® (etrasimod) for the treatment of adult patients with ...